Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells.
Tanaka A, Nishikawa H, Noguchi S, Sugiyama D, Morikawa H, Takeuchi Y, Ha D, Shigeta N, Kitawaki T, Maeda Y, Saito T, Shinohara Y, Kameoka Y, Iwaisako K, Monma F, Ohishi K, Karbach J, Jäger E, Sawada K, Katayama N, Takahashi N, Sakaguchi S.
Tanaka A, et al. Among authors: monma f.
J Exp Med. 2020 Feb 3;217(2):e20191009. doi: 10.1084/jem.20191009.
J Exp Med. 2020.
PMID: 31704808
Free PMC article.